---
document_datetime: 2023-09-21 19:57:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/azacitidine-betapharm-epar-all-authorised-presentations_en.pdf
document_name: azacitidine-betapharm-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.5289839
conversion_datetime: 2025-12-15 21:02:52.890771
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content Pack size

EU/1/19/1416/001 Azacitidine betapharm 25 mg/mL Powder for suspension for injection Subcutaneous use vial (glass) 100 mg 1 vial